CAPRA Education Day 2023

Details Download to Calendar Speakers / Panelists Downloads Sponsors

May 11, 2023 from 8:30am to 4:30pm EDT

Pearson Convention Centre
2638 Steeles Ave E, Brampton,
ONTARIO, L6T 4L7

May 09, 2023, 6:30 pm

All Online registered participants should have received a link to join from customercare@gotowebinar.com. Check system requirements to avoid connection issues on the day of the event. If you have not received the invite in your inbox, check your Junk/Spam folder.

The CAPRA administrator will send an email before the end of May 10 with the link to all presentations and the Agenda.

If you have any questions, contact the CAPRA administrator at administrator@capra.ca.

CAPRA continues to stay committed to providing education to our members and staying connected.

This year, Education Day will take place in person at the Pearson Convention Center on May 11, 2023. This will be a hybrid event.

Registration is now open until May 05, 2023.

This is an opportunity to hear about hot topics of interest in regulatory affairs from Health Canada.

Topics will include the following:

Labelling Bests Practices for Prescription Drug Submissions
Updates and Best Practices for Non-Prescription Drugs
Aligned Reviews Between Health Canada and Health Technology Assessment Organizations
Health Canada’s Approach for Innovative Therapeutic Products that Challenge Regulatory Frameworks
Project Orbis and Access Consortium
Nitrosamine Impurities in Human Pharmaceuticals
Advancing Agile Regulations for Drugs and Medical Devices

This year's Education Day is going to be an amazing event. One of the topics we tried to include in the program was Post-NOC Changes: Quality guidance. However, we were unable to secure a speaker, but Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD) is willing to answer specific questions from CAPRA members and provide a written response.

Please send your questions to administrator@capra.ca by Friday, May 5, 2023. The questions will be forwarded to Health Canada and the response document will be available exclusively to Education Day attendees.

PLEASE NOTE: After the registration deadline, registered attendees will receive an official Go To Webinar link to join Education Day Online.

Check system requirements to avoid connection issues on the day of the event.

In case of unexpected interruptions, such as a power outage, please log back, and the event will restart from where it was disconnected.

See you soon
CAPRA Education Day Committee

Speakers / Panelists

Veronica Yip

Manager of the Labelling Division in the Pharmaceutical Drugs Directorate (PDD
Health Canada
Veronica Yip

Manager of the Labelling Division in the Pharmaceutical Drugs Directorate (PDD
Health Canada

Veronica Yip joined Health Canada in 2001. Veronica is currently the Manager of the Labelling Division in the Pharmaceutical Drugs Directorate (PDD), responsible for the pre-market evaluation of labelling materials submitted for pharmaceutical prescription drugs in accordance with the Food and Drug Act and its Regulations, and the implementation of the Plain Language Labelling (PLL) Regulations. She also manages PDD’s Administrative Submissions Unit (ASU) that screens submissions filed through the administrative pathway. She previously held various regulatory positions in the former Therapeutic Products Directorate (TPD), including Screening Officer and Label Reviewer in the Bureau of Pharmaceutical Sciences, Senior Regulatory Project Manager and acting Manager of the Regulatory Project Management Division.
Taranum Singh

Supervisor in the Labelling Division within the Pharmaceutical Drugs Directorate (PDD)
Health Canada
Taranum Singh

Supervisor in the Labelling Division within the Pharmaceutical Drugs Directorate (PDD)
Health Canada

Taranum Singh is a supervisor in the Labelling Division within the Pharmaceutical Drugs Directorate (PDD) of Health Canada. She has worked at Health Canada for 17 years in a variety of regulatory positions in the PDD. Taranum has a Bachelor’s Degree in Biochemistry from the University of Ottawa.
Jason DiMuzio

Manager, Label Review, Non-prescription Drugs Evaluation Division, Bureau of Product Review and Assessment, Natural and Non-prescription Health Products Directorate, HPFB
Health Canada
Jason DiMuzio

Manager, Label Review, Non-prescription Drugs Evaluation Division, Bureau of Product Review and Assessment, Natural and Non-prescription Health Products Directorate, HPFB
Health Canada

Jason DiMuzio is the Manager of Label Review in the Non-prescription Drugs Evaluation Division, Natural and Non-prescription Health Products Directorate (NNHPD), Health Canada. In his current role, Jason leads a regulatory affairs team responsible for the pre-market assessment of non-prescription drugs, with focus on labelling. Prior to this role, he worked in submission coordination for both non-prescription drugs and natural health products, and in risk communication evaluation. Jason holds a Master of Science in Health: Science, Technology and Policy from Carleton University and an Honours Bachelor’s Degree with Specialization in Chemistry from the University of Ottawa.
Emile Geoffroy

Manager, Planning, Performance and Stakeholder Engagement Division
Health Canada
Emile Geoffroy

Manager, Planning, Performance and Stakeholder Engagement Division
Health Canada

Emile is the manager of the Planning, Performance and Stakeholder Engagement division within the Pharmaceutical Drugs Directorate (PDD) of Health Canada. In addition, he is the Health Canada lead on the HTA alignment initiative. Emile has over 10 years of experience in regulatory affairs with Health Products and Food Branch at Health Canada, in both the generic and innovative pre-market drug space. He has also worked in intellectual property with the Office of Patented Medicines and Liaison at Health Canada. Emile holds a master’s degree in neurobiology from McGill University.
Kenneth Joly

Senior Policy Analyst in the Office of Advanced Therapeutic Products within the Centre for Policy, Pediatrics and International Collaboration at the Biologic and Radiopharmaceutical Drugs Directorate
Health Canada
Kenneth Joly

Senior Policy Analyst in the Office of Advanced Therapeutic Products within the Centre for Policy, Pediatrics and International Collaboration at the Biologic and Radiopharmaceutical Drugs Directorate
Health Canada

Kenneth Joly is a Senior Policy Analyst in the Office of Advanced Therapeutic Products within the Centre for Policy, Pediatrics and International Collaboration at the Biologic and Radiopharmaceutical Drugs Directorate of Health Canada. His main focus is on finding strategic solutions while assessing potential candidates for the Advanced Therapeutic Products framework.
Rebecca Ng

Senior Regulatory Advisor Biologic and Radiopharmaceutical Drugs Directorate
Health Canada
Rebecca Ng

Senior Regulatory Advisor Biologic and Radiopharmaceutical Drugs Directorate
Health Canada

Rebecca is a Senior Regulatory Advisor with the Biologic and Radiopharmaceutical Drugs Directorate, at Health Canada where she coordinates work-sharing for submissions with Health Canada’s international partners. She has a Bachelor of Health Sciences from University of Western Ontario and post-graduate certificate from Seneca’s regulatory program. She joined Health Canada in 2009, and has diverse experience in various operational programs such as controlled substances, cannabis, veterinary drugs, and international files.
Tanya Arcand

Senior Policy Analyst Pediatrics and International Collaboration in Biologic and Radiopharmaceutical Drugs Directorate
Health Canada
Tanya Arcand

Senior Policy Analyst Pediatrics and International Collaboration in Biologic and Radiopharmaceutical Drugs Directorate
Health Canada

Tanya Arcand is a Senior Policy Analyst in the Centre for Policy, Pediatrics and International Collaboration in the Biologic and Radiopharmaceutical Drugs Directorate of Health Canada. She obtained a BSc (Honours) in Biology from the University of Windsor and an MBA from Wayne State University. Tanya has worked at Health Canada since 2007 in a variety of policy, advisory and regulatory positions. Her current role as the Access Consortium Coordinator for Health Canada allows her to apply her diverse regulatory knowledge while assisting in the management of ongoing business and coordination of Access activities at Health Canada.
Stephen Horne

Nitrosamine Quality Subject Matter Expert, Quality Risk Management and Operations Division, Bureau of Pharmaceutical Sciences, Pharmaceutical Drugs Directorate (PDD)
Health Canada
Stephen Horne

Nitrosamine Quality Subject Matter Expert, Quality Risk Management and Operations Division, Bureau of Pharmaceutical Sciences, Pharmaceutical Drugs Directorate (PDD)
Health Canada

Stephen earned a Ph.D. in organic chemistry from the University of Waterloo (ON) in 1991 and completed postdoctoral research at Stanford University (CA, USA). He has held various industrial positions in drug discovery (Syntex Canada), process research and development management (ACIC, Brantford Chemicals), and later Vice-President Global Scientific and Regulatory Affairs (Apotex Pharmachem). He is named as an author or inventor on more than 40 peer-reviewed publications and patents and has held adjunct professor appointments with Western University and the University of Waterloo. Stephen joined Health Canada as a senior scientific reviewer in 2018, supporting Health Canada’s task group managing and responding to the risks associated with nitrosamine impurities in pharmaceuticals. He currently represents Health Canada as a member of the ICH Q9(R1) Plenary Working Party.
Saskia de Morée, MA, LL.B

Manager, Office of Legislative and Regulatory Modernization
Health Canada
Saskia de Morée, MA, LL.B

Manager, Office of Legislative and Regulatory Modernization
Health Canada

Saskia de Morée is a manager of a regulatory policy team at the Office of Legislative and Regulatory Modernization at the Policy, Planning and International Affairs Directorate in Health Canada. She has 18 years of legislative and regulatory development experience with the Government of Canada. She is the regulatory manager on the Agile regulatory project.
Nadia Giancaspro

Senior Policy Analyst, Pharmaceutical Drugs Directorate
Health Canada
Nadia Giancaspro

Senior Policy Analyst, Pharmaceutical Drugs Directorate
Health Canada

Nadia Giancaspro has been with Health Canada since 2001. She is a Senior Policy Analyst within the Pharmaceutical Drugs Directorate of the Health Products and Food Branch. Her latest work has been focused on the development of regulations, policies and guidance on issues related to special access to drugs in Canada, drugs for public and military health emergencies including other emergency-related issues. She is the senior policy analyst on Terms and Conditions under the Agile regulations.
Denis Arsenault, MA

Manager, Policy Development, Biologic and Radiopharmaceutical Drugs Directorate
Health Canada
Denis Arsenault, MA

Manager, Policy Development, Biologic and Radiopharmaceutical Drugs Directorate
Health Canada

Denis Arsenault is a manager in the Office of Policy and International Collaboration within Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD). In this capacity, Mr. Arsenault leads policy development initiatives for BRDD on a number files including regulatory modernization and biosimilar biologic drugs.
Bruce Wozny, MA

Sr. Policy Officer, Marketed Health Products Directorate
Health Canada
Bruce Wozny, MA

Sr. Policy Officer, Marketed Health Products Directorate
Health Canada

Bruce Wozny has been a senior policy officer with the Marketed Health Products Directorate of Health Canada since 2002. Before that he worked in compliance and enforcement of the Food and Drugs Act and Regulations. He is currently working on vigilance policy, including the development of regulations and guidelines for Risk Management Plans.